News

Paul Lammers, MD, MSc, president and chief executive officer, Triumvira Immunologics, discussed the challenges of manufacturing cell therapies.

The FDA has pushed cilta-cel's BLA PDUFA date back by almost 4 months.

The professor from National Taiwan University Hospital discussed further research he would like to do with the gene therapy PTC-AADC.

The vaccination therapy improved progression-free survival by 3.1 months over standard care in 1 patient treated.

The hematologist/oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential of vaccine-based therapies in multiple myeloma.

Partners in the Bespoke Gene Therapy Consortium include the NIH, FDA, private companies such as Pfizer and Biogen, and non-profits.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s expansion into gene therapies.

Ide-cel's March 2021 FDA approval marks a significant advance in relapsed/refractory multiple myeloma treatment.

Rick Fair, president and chief executive officer, Bellicum Pharmaceuticals, discussed the company’s programs and future plans.

The phase 1 study of NTLA-2001 previously showed positive interim data, including serum TTR reductions, which were reported in June 2021.

The assistant professor of medicine at the Medical College of Wisconsin discussed immune-compromising factors that are indigenous to CAR T-cell therapy recipients.

Researchers have developed a corneal epithelial stem cell-derived eye drop therapy for dry eye disease.

Review top news and interview highlights from the week ending October 29, 2021.

The FDA cleared the IND application for HMI-203 in October 2021.

Doctors from University of Washington and Cleveland Clinic discussed targeting CD19 in CAR T-cell therapy for relapsed/refractory DLBCL.

Liso-cel is at the forefront of clinical development for patients with chronic lymphocytic leukemia.

The professor from National Taiwan University Hospital discussed the mechanism of gene therapy in AADC deficiency.

Dabocemagene autoficel has previously received orphan drug, rare pediatric disease, fast track, and regenerative medicine advanced therapy designations.

John Pollack, MD, discusses gene therapy advancements for retinal diseases.

Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the company’s focus on solid tumors and manufacturing cell therapies.

Homology is also developing a gene therapy, HMI-102, being evaluated in the phase 1/2 pheNIX trial.

Josh Ludwig, global director, commercial operations, ScaleReady, discussed making cell and gene therapy widely practical and viable for patients with cancer.

VM202 was found to be particularly effective in treating neuroischemic ulcers.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s partnerships and science.

bluebird bio is also planning to withdraw the marketing authorization for their β-thalassemia therapy, beti-cel, from the EU and UK.

Michael Wang, MD, discussed the evolution of treatment in the MCL space specifically with the emergence of chimeric antigen receptor T cells.

The hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.

The hematologist and medical oncologist discussed next steps with CAR T-cell therapy in penta-refractory multiple myeloma.